Recent Analysts’ Ratings Updates for Royalty Pharma (RPRX)

Royalty Pharma (NASDAQ: RPRX) recently received a number of ratings updates from brokerages and research firms:

• 9/26/2026 – Royalty Pharma was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 9/14/2026 – Royalty Pharma was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 9/12/2026 – Royalty Pharma was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 9/8/2026 – Royalty Pharma had its price target raised by TD Cowen from $65.00 to $68.00. They now have a “buy” rating on the stock.
• 8/30/2026 – Royalty Pharma was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/22/2026 – Royalty Pharma was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/12/2026 – Royalty Pharma had its “buy (b-)” rating reaffirmed by Weiss Ratings.
• 8/8/2026 – Royalty Pharma was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/7/2026 – Royalty Pharma had its price target raised by JPMorgan Chase & Co. from $58.00 to $62.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Royalty Pharma had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $66.00 price target on the stock.
• 8/6/2026 – Royalty Pharma had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $65.00 price target on the stock.
• 8/5/2026 – Royalty Pharma had its “buy” rating reaffirmed by Bank of America Corporation.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Friday, August 14th were paid a dividend of $0.2350 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.94 annualized dividend and a dividend yield of 1.6%. Royalty Pharma’s payout ratio is currently 64.83%.

Insider Buying and Selling

In other news, EVP Marshall Urist sold 9,099 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total value of $508,452.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the sale, the executive vice president directly owned 270,401 shares in the company, valued at $15,826,570.53. This trade represents a 27.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 209,099 shares of company stock valued at $12,358,452. Corporate insiders own 18.84% of the company’s stock.

Royalty Pharma plc is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.

The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions.